𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A pharmacoscintigraphic study of three time-delayed capsule formulations in healthy male volunteers

✍ Scribed by Jason T. McConville; Lee-Ann Hodges; Tamara Jones; Janet P. Band; Bridget O'Mahony; Blythe Lindsay; Alistair C. Ross; Alastair J. Florence; Adrian J. Stanley; Michael J. Humphrey; Clive G. Wilson; Howard N.E. Stevens


Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
272 KB
Volume
98
Category
Article
ISSN
0022-3549

No coin nor oath required. For personal study only.

✦ Synopsis


Three time-delayed capsule (TDC) formulations were investigated in a pharmacoscintigraphic study, using a three-way crossover design in eight healthy male volunteers. Additionally, the pulsed release of a TDC was investigated with time-lapse photography, using a nondisintegrating riboflavin tablet. The photographic study indicated how the release characteristics of the TDC relied on the erosion of a tablet containing hypromellose (HPMC). Each TDC was duel radio labelled with indium-111 and technetium-99 m DTPA complexes, to observe drug release scintigraphically (theophylline was a marker compound). Three formulations, having in vitro dissolution release times of 1.8, 2.9 or 4.0 h were shown to compare favourably with mean in vivo scintigraphic release times of 2.7, 3.0 and 4.0 h for each formulation containing 20, 24 or 35% (w/w) HPMC concentrations respectively. An increase in HPMC concentration was associated with a delayed technetium release time, and followed the same rank order as the in vitro dissolution study. Observed radiolabel dispersion always occurred in the small intestine. In conclusion, the study established that the TDC performs and demonstrates an in vitro-in vivo correlation. Additionally, time and site of release were accurately visualized by gamma scintigraphy, and confirmed with determination of theophylline absorption.


πŸ“œ SIMILAR VOLUMES


Bioequivalence of two oral formulations
✍ Marilyn Lockyer; Saleh Al-Dgither; Eman Al-Gaai; Ahmed Yousuf; Muhammad M. Hamma πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 80 KB πŸ‘ 2 views

## Purpose: The purpose of this randomized, crossover study was to compare the bioavailability of a generic and an innovator formulation of nizatidine 300 mg capsules under fasting conditions. ## Methods: Twenty blood samples per period were collected from 20 healthy, arab male volunteers over 16

Bioequivalence study of three ibuprofen
✍ Peter Bramlage; Adrian Goldis πŸ“‚ Article πŸ“… 2008 πŸ› BioMed Central 🌐 English βš– 694 KB

## Background: This phase i study was designed to determine the bioavailability and bioequivalence of 400 mg eudorlin extra\* (ibuprofen) in comparison to two reference formulations (400 mg nurofen forte and 400 mg migrΓ€nin after single dose administration under fasting conditions in healthy subjec

Pharmacokinetic and pharmacodynamic comp
✍ Idrian GarcΓ­a-GarcΓ­a; Carlos A GonzΓ‘lez-Delgado; Carmen M Valenzuela-Silva; Alin πŸ“‚ Article πŸ“… 2010 πŸ› BioMed Central 🌐 English βš– 297 KB

## Background Interferon (IFN) alpha conjugation to polyethylene glycol (PEG) results in a better pharmacokinetic profile and efficacy. The aim of this study was to compare the pharmacokinetic, pharmacodynamic and safety properties of a new, locally developed, 40-kDa PEG-IFN alpha-2b preparation wi

Preliminary pharmacokinetic study of ibu
✍ Gianfranco Fornasini; Nunzia Monti; Giandomenico Brogin; Maddalena Gallina; Mari πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 155 KB πŸ‘ 2 views

The pharmacokinetics of ibuprofen enantiomers were investigated in a crossover study in which seven healthy male volunteers received single oral doses of 800 mg racemic ibuprofen as a soluble granular formulation (sachet) containing L-arginine (designated trade name: Spedifen), 400 mg (-)R-ibuprofen

A comparative bioavailability study on t
✍ L. Erlacher; H. Templ; D. Magometschnigg πŸ“‚ Article πŸ“… 1995 πŸ› Springer 🌐 English βš– 436 KB

In 12 healthy volunteers the pharmacokinetic parameters of two new sustained-release formulations of disodiummonofluorophosphate (MFP) (B and C) were compared with those of a nonsustained-release reference preparation (A). This randomized study had a single-dose, triple-cross over design and consist